- Home
- HTFL vs ARQT Comparison
HTFL vs ARQT Comparison
Compare HTFL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTFL | ARQT |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | 843 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HTFL | ARQT |
|---|---|---|
| Price | $31.61 | $21.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $38.20 | $34.00 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $27.66 | $34.85 |
| Revenue Next Year | $23.55 | $29.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $20.13 | $12.72 |
| 52 Week High | $41.22 | $31.77 |
Technical Indicators
Market Signals| Indicator | HTFL | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 45.51 |
| Support Level | $28.60 | $21.12 |
| Resistance Level | $32.71 | $21.84 |
| Average True Range (ATR) | 2.17 | 0.99 |
| MACD | 0.18 | 0.11 |
| Stochastic Oscillator | 85.12 | 58.95 |
Price Performance
Historical ComparisonAbout HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.